金域医学公告称，2026年1月5日公司第四届董事会第九次会议审议通过预计与金圻睿2026年度日常关联 交易的议案。2025年公司预计与金圻睿交易2.40亿元，1 - 11月累计已发生交易2.21亿元。2026年预计交 易2.22亿元，其中向其采购商品预计2.20亿元，占同类业务不超15%；向其提供劳务预计150万元，占同 类业务不超5%。金圻睿为佳鉴公司全资子公司，因股东关联关系被认定为关联人，其财务指标正常， 履约能力良好。 ...

Group 1: APA Signing Trends - In 2024, China signed a total of 39 APAs, comprising 12 unilateral and 27 bilateral agreements, showing an increase from 36 APAs in 2023[8] - The number of bilateral APAs signed in 2024 included 22 new agreements and 5 renewals, with 70 bilateral APAs in the intention stage, up by 10 from 2023[8] - The completion rate for APAs in China was 24.20% in 2024, significantly higher than the global average of 18.1%, ranking seventh among reported jurisdictions[8] Group 2: International Cooperation and Industry Focus - From 2005 to 2024, 170 bilateral APAs were signed, with 118 (approximately 70%) involving Asian countries, 33 (20%) with European countries, and 18 with North America[8] - The manufacturing sector remains the primary focus for APA services, with 22 cases involving tangible assets, 12 involving intangible assets, and 8 involving services[8] - The transaction net profit method was the most commonly used transfer pricing method, applied 328 times (83.9% of cases), while other methods were also utilized[8] Group 3: Future Outlook and Compliance - The inventory of bilateral APAs reached 177 cases in 2024, an increase of 28 from 2023, indicating a trend towards stricter acceptance and review processes[11] - Companies are encouraged to submit comprehensive and accurate documentation to expedite the APA application process, particularly focusing on value chain and market premium analyses[11] - Chinese tax authorities are actively enhancing international tax cooperation, with 23 transfer pricing MAP cases concluded in 2024, reflecting a commitment to dispute prevention and resolution[11]

Core Viewpoint - The report outlines the expected daily related transactions of Jiangsu Kangwei Century Biotechnology Co., Ltd. for the year 2025, emphasizing the necessity and fairness of these transactions in supporting the company's operational needs and market competitiveness [1][5][6]. Summary by Sections Daily Related Transactions Overview - The expected amount for daily related transactions in 2025 is estimated at 284 million yuan, with specific categories including raw material purchases and service provisions [1][5]. - The company anticipates a significant increase in transactions with Shanghai Tianhao Biotechnology Co., Ltd. due to new business developments [1][5]. Expected and Executed Transactions for 2024 - The company did not estimate or disclose related transactions for 2024 due to the small amount not meeting the board's review standards [2]. Related Parties and Relationships - Key related parties include Shanghai Tianhao Biotechnology Co., Ltd. and Beijing Kangwei, with established relationships based on shareholding and operational ties [2][3]. Main Content and Pricing Policy of Related Transactions - The main expected transactions for 2025 include vehicle leasing, office space leasing, property management services, technical services, and product sales [5]. - Pricing for these transactions will be based on market principles, ensuring fairness and non-detriment to the company's interests [5][6]. Necessity and Impact of Related Transactions - The anticipated related transactions are deemed necessary for the company's operational activities, contributing to stable business development and enhanced market competitiveness [5][6]. - The pricing of related transactions will follow fair and voluntary principles, ensuring no adverse effects on the company or its shareholders [6]. Review Procedures and Opinions - The board of directors and independent directors have reviewed and approved the related transactions, confirming compliance with legal and regulatory requirements [6][7].